版本:
中国

BRIEF-TESARO submits investigational new drug application for TSR-033 to U.S. FDA

May 1 TESARO Inc-

* TESARO announces submission of investigational new drug application for anti-lag antibody tsr-033 to the u.s. Fda

* A phase 1 clinical study of tsr-033 is planned to begin in mid-2017 Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐